Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world data evaluating the comparative effectiveness of Entyvio® (vedolizumab) and tumor necrosis factor-alpha (TNFα)-antagonist therapy in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD).

Trial Profile

Real-world data evaluating the comparative effectiveness of Entyvio® (vedolizumab) and tumor necrosis factor-alpha (TNFα)-antagonist therapy in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Feb 2018 New trial record
    • 16 Feb 2018 According to a Takeda media release, These analyses were conducted by the VICTORY (Vedolizumab Health OuTComes in InflammatORY Bowel Diseases) Consortium.
    • 16 Feb 2018 According to a Takeda media release, results were presented at at the 13th Congress of the European Crohns and Colitis Organization (ECCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top